These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19657333)

  • 21. A bias correction in testing treatment efficacy under informative dropout in clinical trials.
    Kong F; Chen YF; Jin K
    J Biopharm Stat; 2009 Nov; 19(6):980-1000. PubMed ID: 20183460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials simulation: a statistical approach.
    Westfall PH; Tsai K; Ogenstad S; Tomoiaga A; Moseley S; Lu Y
    J Biopharm Stat; 2008; 18(4):611-30. PubMed ID: 18607794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyzing incomplete longitudinal clinical trial data.
    Molenberghs G; Thijs H; Jansen I; Beunckens C; Kenward MG; Mallinckrodt C; Carroll RJ
    Biostatistics; 2004 Jul; 5(3):445-64. PubMed ID: 15208205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology.
    Leon AC
    J Clin Psychiatry; 2001; 62 Suppl 4():12-6; discussion 37-40. PubMed ID: 11229782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are two antidepressant mechanisms better than one? Issues in clinical trial design and analysis.
    Leon AC
    J Clin Psychiatry; 2004; 65 Suppl 4():31-6. PubMed ID: 15046539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A statistical metadata model for clinical trials' data management.
    Vardaki M; Papageorgiou H; Pentaris F
    Comput Methods Programs Biomed; 2009 Aug; 95(2):129-45. PubMed ID: 19303167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosing model diagnostics.
    Karlsson MO; Savic RM
    Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidimensional assessment of acute and long-term effects in antidepressant drug trials.
    Müller-Oerlinghausen B
    Pharmacopsychiatry; 1994 Jul; 27 Suppl 1():18-20. PubMed ID: 7984692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Power analyses for correlations from clustered study designs.
    Tu XM; Kowalski J; Crits-Christoph P; Gallop R
    Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.
    Lane P
    Pharm Stat; 2008; 7(2):93-106. PubMed ID: 17351897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mood curves of neurotic-depressive patients undergoing treatment with antidepressants: time-series analyses of experience with HTAKA model.
    Möller HJ; Steinmeyer EM
    Pharmacopsychiatry; 1990 Sep; 23(5):215-21. PubMed ID: 2251300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the performance of random-coefficient pattern-mixture models for non-ignorable drop-out.
    Demirtas H; Schafer JL
    Stat Med; 2003 Aug; 22(16):2553-75. PubMed ID: 12898544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity analysis of longitudinal normal data with drop-outs.
    Minini P; Chavance M
    Stat Med; 2004 Apr; 23(7):1039-54. PubMed ID: 15057877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weighted nonparametric maximum likelihood estimate of a mixing distribution in nonrandomized clinical trials.
    Liu C; Xie J; Zhang Y
    Stat Med; 2007 Dec; 26(29):5303-19. PubMed ID: 17497612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.
    Lalovic B; Hutmacher M; Frame B; Miller R
    J Clin Pharmacol; 2011 May; 51(5):706-18. PubMed ID: 20663989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.
    Siddiqui O
    J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.
    Funatogawa T; Funatogawa I; Takeuchi M
    Stat Med; 2008 Dec; 27(30):6351-66. PubMed ID: 18767204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
    Goyal N; Gomeni R
    Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.